EISAI CO. LTD/ JP3160400002 /
| 2024-06-03 12:06:22 PM | Chg. +0.41 | Volume | Bid3:44:32 PM | Ask3:44:32 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.08EUR | +1.03% | 53 Turnover: 2,125.24 |
39.78Bid Size: 126 | 40.19Ask Size: 125 | 11.54 bill.EUR | - | - |
GlobeNewswire
06-02
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Sub...
GlobeNewswire
06-02
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Fil...
GlobeNewswire
05-31
Biogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More ...
GlobeNewswire
05-30
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of P...
GlobeNewswire
05-30
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...
GlobeNewswire
05-29
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Fil...
GlobeNewswire
05-28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen...
GlobeNewswire
05-28
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey ...
GlobeNewswire
05-25
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with ...
GlobeNewswire
05-25
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Again...
GlobeNewswire
05-24
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradio...
GlobeNewswire
05-24
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...
GlobeNewswire
05-23
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...
GlobeNewswire
05-23
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Sub...
GlobeNewswire
05-22
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-14
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinic...
GlobeNewswire
04-29
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
GlobeNewswire
03-29
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GlobeNewswire
03-27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
03-12
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Fai...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
